Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 3, randomized, open-label, comparator-controlled, parallel-group, multicenter study to compare the effects of exenatide and insulin glargine on beta-cell function and cardiovascular risk markers in subjects with type 2 diabetes treated with metformin who have not achieved target HbA1c.

Trial Profile

A phase 3, randomized, open-label, comparator-controlled, parallel-group, multicenter study to compare the effects of exenatide and insulin glargine on beta-cell function and cardiovascular risk markers in subjects with type 2 diabetes treated with metformin who have not achieved target HbA1c.

Completed
Phase of Trial: Phase III

Latest Information Update: 23 Mar 2016

At a glance

  • Drugs Exenatide (Primary) ; Insulin glargine
  • Indications Type 2 diabetes mellitus
  • Focus Biomarker; Pharmacodynamics; Registrational; Therapeutic Use
  • Sponsors AstraZeneca
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 20 Sep 2010 Results were presented at the 46th Annual Meeting of the European Association for the Study of Diabetes.
    • 15 Sep 2010 Data will be presented at the 46th Annual Meeting of the European Association for the Study of Diabetes, according to an Amylin Pharmaceuticals and Eli Lilly media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top